Advanced uterine sarcoma; response to chemotherapy

A 15 year retrospective study of chemotherapy response to multiple regimens employed in 78 evaluable patients with advanced uterine sarcoma was performed. Single agent activity was noted with doxorubicin, methotrexate, and cisplatin (5-11% response rate). Effective multigent regimens included cyclophosphamide, vincristine, doxorubicin, dacarbazine (CYVADIC) (23% response), cisplatin and dacarbazine (21% response) and vincristine, dactinomycin, and cyclophosphamide (VAC) (18% response). There was no difference in response rate among different histologies. More active agents or combinations are needed.